Buy Osphos 51 Mg/Ml Online

We are excited to introduce Osphos 51 mg/mL, a highly effective treatment for equine navicular syndrome. This innovative solution provides a reliable and convenient option for managing the pain and inflammation associated with this common condition in horses. With our worldwide discreet delivery, you can conveniently access Osphos 51 mg/mL from anywhere in the world.

Key Features:

1. Treatment for Equine Navicular Syndrome: Osphos is specifically formulated to address the symptoms of equine navicular syndrome. This syndrome, also known as caudal heel pain, affects the navicular bone and associated structures in the horse’s foot, leading to lameness and discomfort. Osphos provides targeted relief by reducing inflammation and pain associated with this condition.
2. Bisphosphonate Therapy: Osphos contains the active ingredient clodronate, which belongs to a class of drugs known as bisphosphonates. Bisphosphonates are known for their ability to inhibit bone resorption and reduce inflammation. Osphos targets and inhibits the activity of osteoclasts, the cells responsible for breaking down bone tissue, thereby reducing bone pain and promoting healing.
3. Convenient Dosage Form: Osphos 51 mg/mL comes in a convenient liquid formulation that can be easily administered to horses. The precise dosage instructions provided on the label ensure accurate administration. The liquid form allows for easy administration via intramuscular injection, making the treatment process less stressful for both the horse and the caregiver.
4. Rapid Onset of Action: Osphos is known for its rapid onset of action, providing quick relief to horses suffering from navicular syndrome. Within days of administration, horses may experience a reduction in lameness and an improvement in their overall comfort level. This allows for a faster return to normal activity and improved quality of life.
5. Long-lasting Effects: The effects of Osphos are known to be long-lasting, providing extended relief from pain and inflammation associated with equine navicular syndrome. This allows horses to resume their regular activities with increased comfort and reduced risk of recurring lameness.
6. Trusted Quality: EquineCare is committed to providing high-quality equine healthcare products. Osphos 51 mg/mL is sourced from reputable manufacturers and undergoes rigorous quality control measures to ensure its safety, efficacy, and compliance with veterinary standards. You can trust that you are receiving a reliable product that prioritizes the health and well-being of your horses.

Conclusion:
Osphos 51 mg/mL is a highly effective treatment for equine navicular syndrome, providing relief from pain and inflammation associated with this condition. EquineCare is your trusted source for obtaining Osphos and other equine healthcare products, with our worldwide discreet delivery ensuring convenience and accessibility. Help your horses find relief from navicular syndrome and improve their quality of life by incorporating Osphos into their treatment regimen. Place your order today and experience the benefits of this trusted equine therapy.

Why Buy Osphos 51 mg/ml For Horses

Indications for use:

Osphos 51 Mg/Ml – For the alleviation of clinical forelimb lameness associated with the bone resorptive processes of the distal sesamoid (navicular bone) in adult horses.

Contraindications:

• Do not administer intravenously.
• Do not administer to horses less than 4 years of age, due to the absence of data regarding use in growing animals.
• Do not administer to horses with impaired renal function.
• Do not use in cases of known hypersensitivity to the active substance or to any of the excipients.

Special precautions for use in animals:

Use caution when administering bisphosphonates to horses with conditions affecting mineral or electrolyte homeostasis, e.g. hyperkalaemic periodic paralysis, hypocalcaemia.

Special precautions to be taken by the person administering the veterinary medicinal product to animals

Accidental self-injection of this product may increase the risk of obstructed labour in pregnant women and affect fertility in men.

Care should be taken when handling the product to avoid self-injection.

In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.

Route of administration

OSPHOS is administered at 1.8 mg/kg by intramuscular injection up to a maximum dose of 900 mg per horse (one vial). Divide the total volume evenly into three separate injection sites. Discard unused vial contents. OSPHOS is provided in a single use vial and does not contain a preservative.
If there is no response to initial therapy, the horse should be re-evaluated. For horses that initially respond to OSPHOS but do not maintain their clinical improvement for 6 months, OSPHOS may be re-administered at 3 to 6 month intervals based on recurrence of clinical signs. For horses that respond to OSPHOS and maintain clinical improvement for 6 months, OSPHOS should be re-administered after clinical signs recur.

Results

In clinical trials, the success rates were 74.7% for horses treated with OSPHOS and 3.3% for horses treated with saline placebo. The difference in success rates is significant (p-value=0.0028). A horse was considered a treatment success if the lameness grade in the primarily affected limb improved by at least 1 AAEP grade and there was no worsening of lameness grade in the other forelimb on Day 56 post-treatment as compared to the pre-treatment assessment. Of the 86 horses treated with OSPHOS, 8 horses had an improvement of 3 lameness grades, 45 horses improved by 2 lameness grades and 16 horses improved by one lameness grade (raw data).
The clinical effectiveness of OSPHOS noted in the field trial was independent of any corrective shoeing or other therapies for navicular syndrome.
Clinical improvement is most evident at 2 months post-treatment. Of the horses that responded to treatment with OSPHOS in the field study, 65% maintained their level of improvement through the 6 month evaluation.

Side effects

In field studies, the most common side effects reported were signs of discomfort or nervousness, cramping, pawing and/or colic within 2 hours post-treatment (9% of horses treated:  n=10). Eight out of ten of these horses had resolution of their clinical signs with 10 to 15 minutes of hand walking.  In one horse, clinical signs resolved without hand walking. Only one experienced colic requiring treatment. That horse also developed hives and recovered after treatment with flunixin and dexamethasone.